Press Releases

Webcast ImageWebcast
Q4 2016 Dermira, Inc. Earnings Conference Call (Live)
02/28/17 at 4:30 p.m. ET
Q4 2016 Dermira, Inc. Earnings Conference Call
Tuesday, February 28, 2017 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | Archive
DateTitle  
12/22/14Dermira Added to Russell 2000(R) Index
MENLO PARK, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that the company was added to the Russell 2000® Index as part of Russell Investments' quarterly addition of select initial public offering (IPO) companies. Dermira joined the index after the equity markets closed on December 19, 2014. The stock a... 
 Printer Friendly Version
11/12/14Dermira Reports Third Quarter 2014 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today reported financial results for the quarter ended September 30, 2014. "With the clinical advancement of our three late-stage product candidates, the addition of key executives, and the successful completion of our initial public offering, 2014 has bee... 
 Printer Friendly Version
10/02/14Dermira Prices Initial Public Offering
REDWOOD CITY, Calif., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Dermira, Inc. (Nasdaq:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM. In... 
 Printer Friendly Version
08/19/14 Dermira Completes $51 Million Financing and Expands Management Team and Board of Directors
REDWOOD CITY, CA – August 19, 2014 – Dermira, a specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients, today announced that it has completed a $51 million Series C financing. Existing investors Bay City Capital, New Enterprise Associates (NEA), Canaan Partners and UCB S.A. were joined by new investors Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital and other healthcare inve... 
Download PDFPrinter Friendly Version
07/03/14UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)
UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol) Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union Driven by positive Phase 2 results with Cimzia® in psoriasis and the Phase 3 results in psoriatic arthritis1,2 Subject to regulatory approval in psoriasis, Dermira is granted exclusive rights to market Cimzia® to dermatologists in the US and Canada   Bruss... 
Download PDFPrinter Friendly Version
01/12/14Dermira Announces Development and Corporate Progress
Five Ongoing Phase 2 Clinical Trials Targeting Acne, Psoriasis, Atopic Dermatitis, Rosacea and Hyperhidrosis REDWOOD CITY, CA – Dermira, a development-stage biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, announces the progress of three programs into five Phase 2, proof of concept, clinical trials.  The programs include DRM01, a novel, sebum inhibitor for acne; DRM02, a unique PDE4 inhibitor for inflammatory skin ... 
Download PDFPrinter Friendly Version
06/11/13Dermira Raises $35M to Fund Innovation in Dermatology
Existing Investors Joined by Maruho, the Leading Dermatology Company in Japan REDWOOD CITY, CA – June 11, 2013 – Dermira, a development-stage biotechnology company focused on developing and commercializing innovative new therapies in dermatology, today announced that it has raised $35 million of new funding in a Series B financing and related transaction. In this round, new investor, Maruho Co., Ltd. (Maruho), the leading dermatology company in Japan, joins Dermira’s existing investors, Bay C... 
Download PDFPrinter Friendly Version
02/01/13A Win for Skin
Dermira aims $40M at clear target:  Acne BY RON LEUTY San Francisco Business Times Vol. 27, No. 28 February 1–7, 2013 Tom Wiggans and Gene Bauer are putting more skin in the game. The dynamic duo of dermatology drug companies — who led, built and sold Bay Area companies Peplin Inc. and Connetics Corp. — are at it again with Dermira Inc. The Redwood City company, which has lined up more than $40 million in venture funding, has one treatment in an early-stage clinical trial and two mor... 
Download PDFPrinter Friendly Version
10/20/11Dermira Announces a $42m Series A Financing to Fund Therapeutic Advances in Dermatology
October 20, 2011 – Dermira today announced a $42 million Series A financing to support the acquisition, development and commercialization of novel therapeutics in dermatology. The company was founded and seed financed in late 2010 by former members of the Peplin and Connetics leadership teams, including Tom Wiggans, who will serve as Chief Executive Officer, and Dr. Eugene Bauer, who will serve as Chief Medical Officer, together with Bay City Capital. They are joined by Chris Griffith, previousl... 
Download PDFPrinter Friendly Version